Evolving therapeutic paradigms for HIV and HCV.
The continued development of enabling molecular technologies that can be employed to better understand viral replication and the action of currently available therapeutic agents promises to lead to the development of the next generation of drugs with improved therapeutic utility against human immunodeficiency virus (HIV) and hepatitis C virus (HCV). New therapeutic approaches have been developed for treating HIV and HCV infections, but key technical and therapeutic challenges must be addressed to further advance treatment options in each of these areas.
Molla
Akhteruzzaman
A
Antiviral Research, Global Pharmaceuticals Research & Development, Abbott Laboratories, Department R47D, Building AP52N, 200 Abbott Park Road, Abbott Park, IL 60064-6217, USA. akhter.m.molla@abbott.com
Kohlbrenner
William
W
D023241:Antiretroviral Therapy, Highly Active; D000998:Antiviral Agents / Q000494:pharmacology / Q000627:therapeutic use*; D015195:Drug Design; D004359:Drug Therapy, Combination; D023581:HIV Fusion Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D015658:HIV Infections / Q000188:drug therapy; D006526:Hepatitis C / Q000188:drug therapy*; D006801:Humans; D019429:Integrase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D011480:Protease Inhibitors / Q000494:pharmacology / Q000627:therapeutic use
D000998:Antiviral Agents; D023581:HIV Fusion Inhibitors; D019429:Integrase Inhibitors; D011480:Protease Inhibitors